EAU Annual Congress

Litoxetine reduces rate of incontinence episodes

July 23, 2020

Treatment with litoxetine, an investigational oral selective serotonin reuptake inhibitor, led to nearly 22% of patients becoming continent.

68Ga-PSMA-11 PET imaging triggers major changes in management of biochemically recurrent prostate cancer

July 23, 2020

Referring physicians implemented PSMA PET–based treatment changes in 72% of patients.

HoLEP may provide more durable benefit than PVP in patients with BPH

July 23, 2020

The study compared the 2 procedures over 24 months of follow-up.

Improvement in LUTS with aquablation maintained to 2 years with lower risk of sexual dysfunction versus TURP

July 22, 2020

Retreatment rates were low with both aquablation and transurethral resection of the prostate.

Few significant prostate cancers are undetected by mpMRI

July 22, 2020

Cancers that are missed by mpMRI are significantly smaller and less aggressive than those that are detected.

Increased shockwave therapy sessions linked to enhanced benefit for erectile dysfunction

July 21, 2020

In patients with prior exposure to PDE5 inhibitors, increasing the number of sessions of low-intensity shockwave therapy was associated with improving outcomes.

Prostate cancer treatments have differential effect on quality of life, survey indicates

July 21, 2020

The EUPROMS patient-driven quality-of-life study included data from almost 3000 men treated for prostate cancer.

Enzyme inhibition shows promise for overcoming castration resistance in prostate cancer

July 20, 2020

Steroid sulfatase inhibition showed early activity as a precision option in castrate-resistant prostate cancer, including the potential to enhance response to enzalutamide.